Paclib Indications/Uses

5 mL & 16.67 mL: Ovarian Cancer: First-line treatment of advanced ovarian cancer in combination with cisplatin.
Subsequent treatment of advanced ovarian cancer.
Breast Cancer: Adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
Treatment of breast cancer after the failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
For the initial treatment of locally advanced or metastatic breast cancer: In combination with an anthracycline in patients for whom anthracycline therapy is suitable, OR In combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (HER-2) at a 3+ level as determined by immunohistochemistry and for whom anthracycline is not suitable.
Advanced Non-small Cell Lung Cancer (NSCLC): First-line treatment, in combination with cisplatin, of patients with NSCLC who are not candidates for surgery and/or radiation therapy.
AIDS-related Kaposi's Sarcoma: Palliative treatment of advanced or refractory AIDS-related Kaposi's sarcoma in patients who have failed prior liposomal anthracycline therapy.
43.4 mL: The palliative treatment of stage 3 or 4 advanced local carcinoma of the ovary after surgical resection, in combination with Cisplatin.
The palliative management of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.
The treatment of metastatic carcinoma of the breast after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Palliative treatment of advanced non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.